Kataloge von Atlas Antibodies
Triple A Polyclonals for Tissue and Cell Analysis
The Human Protein Atlas (HPA) is a Swedish-based program initiated in 2003 with the aim to map all the human proteins in cells, tissues, and organs and to understand how these proteins are expressed and interact across different parts of the human body. One of the key components of the HPA project is the use of primary polyclonal antibodies for identifying and locating the proteins of interest. Atlas Antibodies is the original manufacturer of Triple A PolyclonalsTM which are human anti rabbit polyclonals developed within the HPA project. The antibodies are validated on all major tissues and organs in the human body. Use this brochure to learn more about the HPA, Atlas Antibodies and about more than 650 newly released Triple A PolyclonalsTM. You can find the full list of new Polyclonals here. Released October 2023.
Neuroscience Marker Panel - White Paper
The nervous system controls and regulates involuntary and voluntary processes in the organism, including higher-order functions such as perception, cognition, emotions, and others. The principal cells of the central nervous system are the neurons, which process and transmit neural signals. Besides, different glial cells are present, including astrocytes, oligodendrocytes, and Schwann cells that support, nourish, and provide electrical isolation to the neural processes. Different types of neurons utilize various kinds of chemical substances to transmit the information (chemical neurotransmitters) acting via multiple receptor subtypes. Atlas Antibodies has developed a panel of PrecisA Monoclonals primary antibodies designed to recognize the main anatomical and neurochemical cell types in rodents and the human nervous system. Released March 2023.
Neural Lineage Development Markers - White Paper
Lineages are the pathways of development and differentiation of neurons and glial cells in the central nervous system. They are defined by the temporal and spatial relationship between the progenitors, early neuronal precursors, and the mature neurons that result from them. Neuronal lineages can be studied in the context of cell fate determination and the processes of development, such as migration, axon guidance, and synaptogenesis. A better comprehension of neuronal lineages is essential to our understanding of the nervous system and how it develops and functions in health and disease. Atlas Antibodies manufactures primary polyclonal and monoclonal antibodies targeting relevant markers in the neural lineage development pathways. In this white paper you can find their selections of PrecisA MonoclonalsTM and TripleA PolyclonalsTM validated in IHC, ICC-IF and WB for tissue and cell analysis. All antibodies are paired with their specific PrEST AntigensTM. Released March 2023.
Primary Antibodies for Neuroscience
Neuroscience studies the nervous system as well as the disorders and injuries that affect its functioning. Atlas Antibodies offers a large catalog of primary monoclonal and polyclonal antibodies targeting a wide spectrum of markers relevant in neuroscience research and tailored for use on human and rodent tissue samples. These antibodies are highly validated and show high specificity and selectivity for their target proteins. Updated January 2023.
Primary Antibodies targeting Ovarian Carcinomas - White Paper
Gynecologic cancers originate in the female reproductive organs. The 5 main types of gynecologic cancers are cervical, ovarian, uterine, vaginal, and vulvar. Of these, ovarian cancer is the deadliest form causing more deaths than any other cancer of the female reproductive system with around two-thirds of patients diagnosed with advanced disease due to late presentation. Furthermore, around 90% of patients develop recurrence and eventually become chemoresistant. Therefore, there is a high demand to identify biomarkers specific to this disease for screening for early detection, as well as new therapeutic targets. The capacity of these biomarkers to predict the existence, stages, and associated therapeutic efficacy of ovarian cancer would enable improvements in the early diagnosis and survival of ovarian cancer patients. This white paper presents Atlas Antibodies' selected PrecisA MonoclonalsTM and TripleA PolyclonalsTM targeting ovarian cancers. Released November 2022.
Primary Antibodies for Cell Biology
Discover the organelle proteome and find information about primary antibodies suitable as markers for each of the individual proteomes of the organelles and subcellular structures classified within the subcellular section of the human protein atlas (HPA), together with beautiful examples of immunofluorescent staining images. Released November 2022.
Atlas Antibodies in Breast Cancer Research
The products from Atlas Antibodies are used by scientists working to understand breast cancer. In this brochure, you can find antibodies related to the field of breast cancer research together with publication references. The antibodies include the established clinical breast cancer markers ESR1, HER2, Ki67, PGR. Antibodies are selected either based on a published reference or for the relevance in breast cancer of the corresponding target protein. Released October 2022.
Atlas Antibodies in Colorectal Cancer Research
A large number of the antibodies provided by Atlas Antibodies are relevant for scientists studying colorectal cancer. In this brochure, you can find antibodies related to the field of colorectal cancer research together with publication references. Antibodies are selected either on a reference/article-basis or on colon cancer relevance for the corresponding target protein. Released October 2022.
PrecisA Monoclonal Antibodies - Precise, Accurate, Targeted
PrecisA MonoclonalsTM are mouse monoclonal primary antibodies developed for a number of carefully selected targets. Atlas Antibodies selects the relevant antibodies for each target and takes special care in offering clones recognizing unique non-overlapping epitopes and/or isotypes. Thanks to a stringent production process and characterization procedure, PrecisA MonoclonalsTM provide outstanding performance in approved applications, defined specificity, secured continuity, and stable supply. Released August 2022.
Primary Antibodies for Cancer Research
Atlas Antibodies offer an extensive catalog of primary antibodies targeting a broad spectrum of markers relevant in cancer research and tailored for use on human and rodent tissue samples. Explore the selection of Triple A Polyclonals antibodies that are suitable markers for 17 human cancer types and learn about the top genes with favorable and unfavorable prognoses in cancer. Released August 2022.
Neuroinflammation - White Paper
Our understanding of the molecular pathogenesis of neuroinflammation is growing steadily. Progress in different areas of basic research, new animal models, and the generation of specific antibody markers to target essential proteins help to find and improve the treatment of patients with neuroimmunological diseases. This white paper discusses the role of microglia, oligodendrocytes, and astrocytes in the neuroinflammatory processes highlighting the relevant antibody markers with a particular focus on multiple sclerosis. Released July 2022.
Centriolar Satellite Markers - White Paper
The centrosome is the organelle that acts as the primary microtubule-organizing center of the cell. The centrosome includes the centrioles (the structures that enable the formation of spindle fibers) along with a dense mass of protein called the peri-centriolar material, now known as centriolar satellites. The term “centriolar satellites” was coined in the second half of the 20th century to name the 70–100 nm electron-dense particles in diameter surrounding the centrosome. Centriolar satellites contain several centrosomal proteins and are the core structural elements of centrosomes and cilia. Atlas Antibodies offers numerous markers targeting centriolar satellites proteins, some of which are highlighted in this white paper. Released March 2022.
Glioma Markers - White Paper
Gliomas are one of the most aggressive and lethal solid tumors of the central nervous system. Despite the alarming numbers, the molecular pathogenetic mechanisms of gliomas are not yet fully elucidated. Nowadays, several approaches aim to understand the biology of the disease and identify promising markers, which may provide effective novel therapies. This white paper summarizes the recent developments in glioma classification and the key molecular markers for glioma stratification. Next, it highlights the glioma proteome with a list of relevant genes with favorable and unfavorable prognostic values in glioma. It then focuses on the glioma tumor microenvironment that may provide helpful insights when developing novel therapeutic strategies. Released December 2021.